Studied doses vs folklore doses
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
Every dose below is either what a label or trial actually specifies, or what real-world users actually take, each at its own evidence grade. No mouse conversion appears because no valid one exists.
| regimen | who_and_context | evidence_grade | what_it_showed | Source |
|---|---|---|---|---|
| 6 mg loading, then 2 mg daily | Renal transplant, low-to-moderate risk (FDA label) | FDA label | Halved acute rejection in pivotal trials, with the label's full warning ledger | source |
| Up to 15 mg loading, then 5 mg daily | Renal transplant, high immunologic risk (FDA label) | FDA label | Approved high-risk regimen with trough-guided adjustment | source |
| 2 mg daily, titrated to troughs 5-15 ng/mL | LAM (FDA label; MILES trial) | Human RCT | Stabilized lung function while on drug; decline resumed after stopping | source |
| 1 mg daily, 8 weeks | Adults 70-95, safety pilot (Kraig 2018) | Human RCT | Feasibility and short-term safety; no efficacy endpoints moved | source |
| 5 or 10 mg compounded, once weekly, 48 weeks | Healthy adults, PEARL RCT (AgelessRx) | Human RCT | Primary endpoint missed; AEs similar to placebo; secondary signals in women | source |
| Commercial 2-8 mg or compounded 5-15 mg, weekly | Real-world longevity users (blood-level cohorts) | Human PK | Compounded delivers about one third the exposure per mg; levels peak day 2 | source |
| Typical folklore: 5-7 mg weekly 'for longevity' | Off-label prescribing economy; 333-user survey documents the practice | Human observational | Tolerability by self-report; zero outcome data for the schedule | source |
| 4.7 / 14 / 42 ppm of chow | ITP mice (the lifespan results) | Animal | The lifespan extensions; NOT convertible to a human mg dose, and this site does not convert it | source |